P0636 Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study
Fernando Magro(Universidade do Porto), Séverine Vermeire(KU Leuven), Parambir S. Dulai(Northwestern Medicine), Britta Siegmund(Humboldt-Universität zu Berlin), K Shan(Abivax (France)), Luc Biedermann(University of Zurich), Takashi Hisamatsu(Okayama University), Fabio Cataldi(Abivax (France)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Herbert Tilg(Innsbruck Medical University), Silvio Danese(IRCCS Ospedale San Raffaele), D Jacobstein(Abivax (France)), Christian G. Rabbat(Abivax (France)), B E Sands(Icahn School of Medicine at Mount Sinai), M Dubinsky
Cited by 1
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|Hepatology|2017|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k